Clinical pharmacology of piroxicam-β-cyclodextrin. Implications for innovative patient care

Clinical Drug Investigation

Volumn 19, Issue SUPPL. 2, 2000, Pages 27-31

  McEwen, John ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG CARRIER; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PIROXICAM BETA CYCLODEXTRIN;

ANALGESIA; BLEEDING; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SOLUBILITY; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; HUMAN; INFLAMMATION; NONHUMAN; PAIN; PHOTOSENSITIVITY; PRIORITY JOURNAL; REVIEW;

EID: 0034089426     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200019002-00004     Document Type: Review

References (41)

1. British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary. London, 1999
2. Anonymous. Piroxicam. In: Dollery CT, editor. Therapeutic drugs. Edinburgh: Churchill Livingstone, 1991: 136-40
3. Cram DJ. The design of molecular hosts, guests and their complexes. J Inclusion Phenomena 1988; 6: 397-413
4. Rajewski RA, Stella VJ. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J Pharm Sci 1996; 85: 1142-69
5. Stella VJ, Rajewski RA. Cyclodextrins: their future in drug formulation and delivery. Pharm Res 1997; 14: 556-67
6. Acerbi D, Bovis G, Carli F, et al. Biopharmaceutical optimisation of β-cyclodextrin inclusion compounds. Drug Invest 1990; 2 Suppl. 4: 29-36
7. Woodcock BG, Acerbi C, Merz, PG, et al. Supermolecular inclusion of piroxicam with β-cyclodextrin: pharmacokinetic properties in man. Eur J Rheumatol Inflamm 1993; 12: 12-28
8. Acerbi D. Pharmacokinetic profile of piroxicam-β-cyclodextrin. Drug Invest 1990; 2 Suppl. 4: 42-9
9. Acerbi D, Lebacq Jr E, Rondelli I, et al. Rapid absorption profile of piroxicam from its β-cyclodextrin complex. Drug Invest 1990; 2 Suppl. 4: 50-5
10. Deroubaix X, Stockis A, Allemon AM, et al. Oral bioavailability of CHF 1194, an inclusion complex of piroxicam and β-cyclodextrin, in healthy subjects under single dose and steady-state conditions. Eur J Clin Pharmacol 1995; 47: 531-6
11. Acerbi D, Ventura P. β-Cyclodextrin-piroxicam: pharmacokinetic profile. J Drug Develop 1991; 4 Suppl. 1: 17-9
12. Gerloczy A, Fonagy A, Keresztes P, et al. Absorption, distribution, excretion and elimination of orally administered 14C-β-cyclodextrin in rat. Arzneimittelforschung 1985; 35: 1042-7
13. Bauduin H, Farnaey J-P. Comparison of the analgesic effects of β-cyclodextrin-piroxicam, sodium naproxen and potassium diclofenac utilizing the dental pain model. J Pharm Care Pain Symptom Control 1995; 3: 19-29
14. Tamburro P, Galasso G. Studio clinico controllato sull'effetto antalgico del complesso piroxicam-beta-ciclodestrina nel dolore acuto musculo-scheletrico e/o articolare. Reumatologo 1989; 6: 237-41
15. Costa S, Mioli M, Ravaioli R, et al. Prostaglandin synthetase inhibitor piroxicam beta-cyclodextrin in the treatment of primary dysmenorrhea. Curr Ther Res 1987; 42: 156-64
16. Di Matteo L, Fratelli V, Oliani C, et al. La spalla dolorossa semplice: efficacia antalgica e tollerabilità del trattamento con il complesso piroxicam-beta-ciclodestrina. Arch Med Interna 1989; 41 (4): 261-72
17. La Montagna G, Tirri G, Cacae E, et al. Quality of life assessment during six months of NSAID treatment [Gonarthrosis and Quality of Life (GOAL) Study]. Clin Exp Rheumatol 1998; 16: 49-54
18. Marcucci M, Panelli P, Cambini S. Clinical experience in the treatment of dental pain. Clin J Pain 1991; 7 Suppl. 1: S72-6
19. Michelacci M, Boscarino G, Acerbi D, et al. Analgesic effect and pharmacokinetics of a piroxicam beta-cyclodextrin oral formulation in post-surgical pain. Clin Trials J 1990; 27: 176-86
20. Tamburro P, Galasso G. Efficacia e tollerabilità del piroxicam-beta-ciclodestrina nel trattamento del dolore muscolo-scheletrico. Reumatologo 1989; 10: 104
21. Giacovazzo M, Marteletti V, Zaurito V, et al. Effetto antalgico acuto del complesso piroxicam-beta-ciclodestrina nel trattamento della cefalea. G Neuropsicofarmacol 1989; 11: 31-5
22. Dolci G, Ripari M, Pacifici L, et al. Evaluation of piroxicam-β-cyclodextrin, piroxicam, paracetamol and placebo in post-operative oral surgical pain. Int J Clin Pharm Res 1994; 14: 185-91
23. Nappi G, Manzoni GC, Oliani C. Piroxicam-β-cyclodextrin in the treatment of headache. Drug Invest 1990; 2 Suppl. 4: 78-95
24. Tiengo M. Review of the analgesic effects of piroxicam-β-cyclodextrin. Drug Invest 1990; 2 Suppl. 4: 61-6
25. Passeri M. Piroxicam-β-cyclodextrin in rheumatology. Drug Invest 1990; 2 Suppl. 4: 86-8
26. Costa S, Zinelli G, Bufalino L. Piroxicam-β-cyclodextrin in the treatment of dysmenorrhoea. Drug Invest 1990; 2 Suppl. 4: 73-8
27. Wyss V, Ganzit GP. Piroxicam-β-cyclodextrin in sports medicine and traumatology. Drug Invest 1990; 2 Suppl. 4: 67-72
28. Lee CR, Balfour JA. Piroxicam-β-cyclodextrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in rheumatic diseases and pain states. Drugs 1994; 48: 907-29
29. Garcia Rodriguez LA. Variability in risk of gastrointestinal complications with different nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104 (3A): 30S-34S
30. Santucci L, Fiorucci S, Chiucciu S, et al. Placebo-controlled comparison of piroxicam-β-cyclodextrin, piroxicam and indomethacin on gastric potential difference and mucosal injury in humans. Dig Dis Sci 1992; 37: 1825-32
31. Muller P, Simon B. Vergleichende endoskopische Untersuchung zur gastroduodenalen Vertraglichkeit von Piroxicam-β-cyclodextrin vs Piroxicam. Z Rheumatol 1997; 56: 76-9
32. Nervetti A, Ambanelli U, Ugolotti G. Assessment of gastric mucosal damage by a new inclusion complex of piroxicam with β-cyclodextrin: a functional study by a scintigraphic method. J Drug Dev 1991; 4 Suppl. 1: 39-42
33. Warrington S, Debbas N, Farthing M, et al. Piroxicam-β-cyclodextrin: effects on gastrointestinal blood loss and gastric mucosal appearance in healthy men. Int J Tissue React 1991; 13: 243-8
34. Patoia L, Clausi G, Farroni F, et al. Comparison of faecal blood loss, upper gastrointestinal mucosal integrity and symptoms after piroxicam β-cyclodextrin, piroxicam and placebo administration. Eur J Clin Pharmacol 1989; 36: 599-604
35. Varela P, Amorim I, Massa A, et al. Piroxicam-β-cyclodextrin and photosensitivity reactions. Contact Dermatitis 1998; 38: 229
36. Umile A. Piroxicam-beta-cyclodextrin and photosensitivity reactions [letter and reply]. Contact Dermatitis 1999; 40: 340-2
37. Christian AE, Haynes MP, Phillips MC, et al. Use of cyclodextrins for manipulating cellular cholesterol content. J Lipid Res 1997; 38: 2264-72
38. Totterman AM, Schipper NG, Thompson DO, et al. Intestinal safety of water-soluble beta-cyclodextrins in paediatric oral solutions of spironolactone: effects on human intestinal Caco-2 cells. J Pharm Pharmacol 1997; 49: 43-8
39. Catala I, Domingo N, Juste C, et al. Effect of beta-cyclodextrin dietary supplementation on biliary proteins and their resulting cholesterol nucleating activity in pigs. Biochem Biophys Acta 1998; 1394: 74-84
40. Toyoda K, Shoda T, Uneyama C, et al. Carcinogenicity study of beta-cyclodextrin in F344 rats. Food Chem Toxicol 1997; 35: 331-6
41. Singh G, Ramey DR, Morfield D, et al. Gastrointestinal complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med 1996; 156: 1530-6